![](/wp-content/uploads/2019/07/pfizer-440x293.jpg)
Pfizer to combine off-patent drug business with Mylan
As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan– a generic drugmaker. Pfizer shareholders would own
As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan– a generic drugmaker. Pfizer shareholders would own